Routine

Anogenital warts (HPV)

HPV warts · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Anogenital warts are caused by low-risk human papillomavirus types (6/11). They are benign but recurrent; treatment is cosmetic/symptomatic. Vaccination prevents them and the high-risk types causing cancer.

Red flags

  • Pigmented, indurated, ulcerated or bleeding lesion (neoplasia)
  • Rapid growth or treatment resistance
  • Immunosuppression with extensive disease
  • Obstructive internal/urethral lesions
  • Lesions in a child raising safeguarding concern

Assessment

Differential diagnosis

  • Condylomata lata of secondary syphilis
  • Molluscum contagiosum
  • Skin tags / pearly penile papules
  • Intraepithelial neoplasia
  • Seborrhoeic keratosis

Investigations

  • Clinical diagnosis by inspection
  • Full STI screen including HIV and syphilis
  • Biopsy if atypical, pigmented, bleeding or treatment-resistant
  • Proctoscopy/speculum exam if internal lesions suspected
  • Cervical screening per programme
  • Consider anal cytology/HRA in high-risk groups

Management

  • Confirm diagnosis clinically; biopsy atypical lesions
  • Screen for coexisting STIs and HIV
  • Discuss treatment options and that they clear virus-driven lesions, not infection
  • Offer patient-applied topical therapy or clinic-based ablative treatment
  • Avoid podophyllotoxin/imiquimod in pregnancy; use physical ablation instead
  • Treat according to number, site and keratinisation of lesions
  • Counsel on recurrence, transmission and condom limitations
  • Offer HPV vaccination where eligible
  • Arrange cervical/anal screening as indicated
  • Review response and switch modality if poor clearance
  • Address psychosexual concerns
  • Encourage partner awareness (routine screening, not treatment of warts)

Drugs & doses

Imiquimod 5% cream applied 3 times weekly, washed off after 6-10 h, up to 16 weeks
Podophyllotoxin 0.5% solution/0.15% cream twice daily for 3 days then 4 days off, up to 4-6 cycles
Cryotherapy with liquid nitrogen (clinic, repeated weekly)
Trichloroacetic acid 80-90% applied in clinic
HPV vaccine (9-valent) per schedule for prevention

Disposition

Outpatient sexual health/dermatology; routine; refer atypical lesions for biopsy.

Complications & pitfalls

  • Recurrence after treatment
  • Local skin reaction/scarring from therapy
  • Psychological distress
  • Rare giant condylomata (Buschke-Lowenstein)
  • Associated high-risk HPV intraepithelial neoplasia

Exam pearls

  • Warts are low-risk HPV; cancers arise from high-risk types (16/18)
  • Vaccination prevents both warts and HPV-related cancers
  • No single treatment is clearly superior; tailor to patient and lesion
  • Treating warts does not eliminate HPV or guarantee no transmission
  • Avoid imiquimod/podophyllotoxin in pregnancy

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.